"We are pleased with the DMC recommendations, which we believe support the potential for (tumor-treating fields) to make a significant difference in treatment outcomes for patients with non-small cell lung cancer, whether used together with immune checkpoint inhibitors or (a chemo treatment called) docetaxel," Novocure Executive Chairman William Doyle said in a written statement.